State Street SPDR S&P Pharmaceuticals ETF XPH
67.45 USD -1.37 (-1.99%)
Nov 12, 2026, 3:21 PM EST
67.24 Day range 68.67
50.04 52-week range 74.35
- YTD
- +20.42%
- 1 year
- +32.49%
Benzinga news
benzinga.com Two Years to Build or Pay 200% — Which US Pharma Stocks Win? Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
benzinga.com Why Is Organon Stock Skyrocketing Monday? Sun Pharma to acquire Organon in an all-cash deal valued at $11.75 billion. OGN shares rise on the acquisition news.
benzinga.com Why Is Amneal Pharmaceuticals Stock Gaining Today? Amneal Pharmaceuticals rises premarket after $1.1B Kashiv BioSciences deal to expand biosimilars platform and tap $300B biologics opportunity, while raising FY26 outlook.
benzinga.com Axsome Stock Climbs On Schizophrenia Drug Deal With Takeda Axsome gains after securing global rights to balipodect from Takeda, advancing schizophrenia pipeline amid bullish analyst targets.
benzinga.com Prestige Bets $1 Billion On World's Most Iconic Nasal Strip Prestige Consumer Healthcare acquires Breathe Right brand for $1.045 billion. Deal expands OTC portfolio into sleep & breathing categories.
benzinga.com Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks' Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
benzinga.com Why Health Care ETFs Aren't Panicking Over Big Pharma's Price Cuts Healthcare ETFs stay resilient as Big Pharma agrees to Medicaid drug price cuts. Here's what is cushioning ETFs despite pricing pressure.
benzinga.com Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
benzinga.com Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
benzinga.com Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
benzinga.com Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
benzinga.com Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
benzinga.com Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
benzinga.com Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
benzinga.com Trump Sparks New Chapter In Transatlantic Trade War: What The US Buys From Europe Trump announced 50% tariffs on all EU imports starting June 1, citing high trade deficits and unfair barriers. Pharmaceutical products and cars most exposed.
benzinga.com Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
benzinga.com Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
benzinga.com ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.
benzinga.com Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
benzinga.com Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On? Biopharma is seen as a safe haven for investors due to its high-margin business model and flexibility in dealing with potential tariffs. Other key questions remain.
benzinga.com Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027 Perrigo Company shares surged after issuing financial targets for 2025 & 2025-2027 on investor day. Expect sales growth, EPS, and margin expansion. 'Three-S' plan will enhance cash flow & shareholder…
benzinga.com Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock rally.
benzinga.com Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits The Supreme Court has rejected Purdue Pharma's bankruptcy plan, exposing the Sackler family to lawsuits over their role in the opioid crisis. This decision impacts victims, state and local…
benzinga.com Organon Beats On Q1, Women's Health Leads the Charge Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.
benzinga.com Here Are The Best-Performing Industry ETFs And Major Stock Contributors In April It's a good time to look at how the major U.S. stock industry ETFs performed this month, as April comes to an end. In April, we saw the broader U.S.
benzinga.com Chevron, Uber Technologies, And A Way To 'Bet Against The Big Guys' Are CNBC's 'Final Trades' On CNBC’s “Halftime Report Final Trades,” Bryn Talkington of Requisite Capital Management said that each name is around 3% in the SPDR S&P Pharmaceuticals ETF (ARCA: XPH). The pharma sector is a…
benzinga.com 3 Pharmaceutical ETFs That Could Be Due For A Rebound These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. Support is a large concentration of buyers who have gathered around the same price level. At support…
benzinga.com Big Pharma In Canada Offers C$1B In Last Attempt To Stop Drug Pricing Crackdown The pharmaceutical industry has delivered a C$1 billion ($761 million) proposal to the Canadian government in an attempt to stave off an upcoming price crackdown, Reuters reported- benzinga.com 'Fast Money Halftime Report' Picks For September 25
benzinga.com Biotech Stocks Convalescing After Wednesday's Trump-Inspired Biotech Selloff 
benzinga.com Last Night's Election - A Series Of Fortunate Events For Big Pharma - benzinga.com Getting Into The Drug Business: From NDAs To PDUFA Dates
- benzinga.com Morgan Stanley: How Much Would Pharma Companies Lose If The Whole Country Got VA Drug Prices?
- benzinga.com ETFs For The Next Pharma Takeover Candidates
- benzinga.com 3 Ways To Profit From Merger Activity In The Pharmaceutical Sector
- benzinga.com Pharmaceutical Industry Expected To Collect Billions From Obamacare
- benzinga.com S&P: Heaping Praise For Some Health Care ETFs
- benzinga.com Interesting Similarities Among 2013's Top-Performing ETFs
- benzinga.com Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)
benzinga.com Fifteen Health Care ETFs Trading Near 52-Week Highs - benzinga.com Twelve Health Care ETFs Trading Near 52-Week Highs
- benzinga.com Alchemy Real-Time Stream From Monday, 10/11/10
- benzinga.com Eli Lilly (LLY) Is Facing Big Challenges